Logo image
Back
Antiviral therapies targeting host ER alpha-glucosidases: Current status and future directions
Journal article   Open access   Peer reviewed

Antiviral therapies targeting host ER alpha-glucosidases: Current status and future directions

Jinhong Chang, Timothy M. Block and Ju-Tao Guo
Antiviral research, v 99(3), pp 251-260
28 Jun 2013
DOI: https://doi.org/10.1016/j.antiviral.2013.06.011
PMID: 23816430
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1016/j.antiviral.2013.06.011View
Published, Version of Record (VoR)Open Access (License Unspecified),  Open

Abstract

antiviral therapy ER α-glucosidases filovirus flavivirus imino sugars viral hemorrhagic fever
• ER α-glucosidases are essential host factors for the morphogenesis of many enveloped viruses. • Imino sugars are competitive inhibitors of the ER α-glucosidases I and II. • Broad-spectrum antiviral efficacies of imino sugars have been demonstrated in vitro , and in vivo. • Strategies for development of potent and specific ER α-glucosidase inhibitors have been proposed. • Targeting glucosidase is promising for viral hemorrhagic fever and respiratory infections. Endoplasmic reticulum (ER)-resident α-glucosidases I and II sequentially trim the three terminal glucose moieties on N-linked glycans attached to nascent glycoproteins. These reactions are the first steps of N-linked glycan processing and are essential for proper folding and function of many glycoproteins. Because most viral envelope glycoproteins contain N-linked glycans, inhibition of ER α-glucosidases with derivatives of 1-deoxynojirimycin (DNJ) or castanospermine (CAST), two well-studied pharmacophores of α-glucosidase inhibitors, efficiently disrupts the morphogenesis of a broad spectrum of enveloped viruses. Moreover, both DNJ and CAST derivatives have been demonstrated to prevent the death of mice infected with several distinct flaviviruses and filoviruses and suppress the multiplication of several other species of viruses in infected animals. N -Butyl derivative of DNJ ( N B-DNJ) and 6 O-bytanoyl prodrug of CAST (Bu-CAST) have been evaluated in human clinical trials for their antiviral activities against human immunodeficiency virus and hepatitis C virus, and there is an ongoing trial of treating dengue patients with Bu-CAST. This article summarizes the current status of ER α-glucosidase-targeted antiviral therapy and proposes strategies for development of more efficacious and specific ER α-glucosidase inhibitors as broad-spectrum, drug resistance-refractory antiviral therapeutics. These host function-targeted, broad-spectrum antiviral agents do not rely on time-consuming etiologic diagnosis, and should therefore be particularly promising in the management of viral hemorrhagic fever and respiratory tract viral infections, medical conditions that can be caused by many different enveloped RNA viruses, with a short window for medical intervention.

Metrics

16 Record Views
100 citations in Web of Science
102 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Pharmacology & Pharmacy
Virology
Logo image